Abu Dhabi's ADQ to invest $75 mn in Biocon Biologics for 1.8% stake

Kiran Mazumdar-Shaw, executive chairperson, Biocon
Biopharmaceutical major Biocon said on Thursday the board of its subsidiary Biocon Biologics has approved a capital injection of $75 million from Abu Dhabi-based ADQ.

According to the terms of the proposed agreement, ADQ will get a 1.8 per cent stake in the biosimilar business, valuing Biocon Biologics at a post money valuation of $4.17 billion. “This investment is an endorsement of the value that the Biocon Biologics business has built as a fully integrated pure-play biosimilars company and will enable us to expand our capabilities further. We are committed to pursue our affordable innovation model to generate savings for the healthcare systems worldwide,” said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon.

This is the fourth fund raise by the Bengaluru-based company in 12 months. Last year, private equity players True North and Tata Capital had picked up minority stakes in Biocon Biologics for $75 million and $30 million, respectively. The company board also approved a capital injection of $150 million from global banking and investment firm Goldman Sachs in November.

“The ADQ equity funding in Biocon Biologics endorses the value of our business model and strengthens our resolve to be the global leader in biologics, delivering affordable access to innovative and inclusive healthcare solutions, transforming patients’ lives,” said Christiane Hamacher, CEO & Managing Director, Biocon Biologics.

Biocon Biologics, which plans an IPO, has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. Last year, its Insulin Glargine was commercialised in the US, which opened up a $2.2 billion opportunity for the R&D rich company. The company is currently working on a pipeline of two more products in the insulin portfolio namely Aspart and Lispro, both rapid acting insulin analogs. The company aspires to transform healthcare through affordable innovative solutions as well as impact five million patients’ lives by FY22. 

“Biocon Biologic’s proven R&D track record and partnerships worldwide provide us with an opportunity to benefit from the biosimilar sector that is set to grow as patents of originator biologics expire and patients demand lower priced drugs globally,” said H.E. Mohamed Hassan Alsuwaidi, Chief Executive Officer of ADQ.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel